O	0	1	A
O	2	7	phase
O	8	10	II
O	11	17	breast
O	18	24	cancer
O	25	40	chemoprevention
O	41	46	trial
O	47	49	of
O	50	54	oral
B-intervention	55	60	alpha
I-intervention	60	61	-
I-intervention	61	84	difluoromethylornithine
O	84	85	:
O	86	92	breast
O	93	99	tissue
O	99	100	,
O	101	108	imaging
O	108	109	,
O	110	113	and
O	114	119	serum
O	120	123	and
O	124	129	urine
O	130	140	biomarkers
O	140	141	.

O	142	143	A
O	144	150	double
O	150	151	-
O	151	156	blind
O	157	167	randomized
O	168	173	Phase
O	174	176	II
O	177	192	chemoprevention
O	193	198	trial
O	199	201	of
O	202	207	alpha
O	207	208	-
O	208	231	difluoromethylornithine
O	232	233	(
O	233	237	DFMO
O	237	238	)
O	239	242	was
O	243	252	conducted
O	253	255	in
O	256	257	a
O	258	263	group
O	264	266	of
B-eligibility	267	272	women
I-eligibility	273	275	at
I-eligibility	276	280	high
I-eligibility	281	285	risk
I-eligibility	286	289	for
I-eligibility	290	301	development
I-eligibility	302	304	of
I-eligibility	305	311	breast
I-eligibility	312	318	cancer
O	318	319	.

O	320	324	DFMO
O	325	327	is
O	328	330	an
O	331	343	irreversible
O	344	353	inhibitor
O	354	356	of
O	357	366	ornithine
O	367	380	decarboxylase
O	380	381	,
O	382	385	the
O	386	394	limiting
O	395	401	enzyme
O	402	404	of
O	405	414	polyamine
O	415	424	synthesis
O	425	429	that
O	430	432	is
O	433	438	often
O	439	441	up
O	441	442	-
O	442	451	regulated
O	452	454	in
O	455	461	breast
O	462	468	cancer
O	468	469	.

O	470	475	Study
O	476	484	entrants
O	485	489	were
O	490	498	required
O	499	501	to
O	502	506	have
O	507	513	random
O	514	525	periareolar
O	526	530	fine
O	530	531	-
O	531	537	needle
O	538	548	aspiration
O	549	557	cytology
O	558	563	prior
O	564	566	to
O	567	572	entry
O	573	577	that
O	578	587	exhibited
O	588	599	hyperplasia
O	600	602	or
O	603	614	hyperplasia
O	615	619	with
O	620	626	atypia
O	626	627	,
O	628	630	as
O	631	635	well
O	636	638	as
O	639	640	a
O	641	650	mammogram
O	651	654	and
O	655	663	clinical
O	664	670	breast
O	671	675	exam
O	676	682	judged
O	683	685	as
O	686	689	not
O	690	700	suspicious
O	701	704	for
O	705	711	breast
O	712	718	cancer
O	719	722	and
O	723	725	no
O	726	734	clinical
O	735	742	hearing
O	743	747	loss
O	747	748	.

O	749	757	Subjects
O	758	762	were
O	763	773	randomized
O	774	776	to
O	777	778	6
O	779	785	months
O	786	788	of
O	789	793	oral
O	794	798	DFMO
O	799	800	(
O	800	801	0
O	801	802	.
O	802	803	5
O	804	805	g
O	805	806	/
O	806	807	m
O	807	808	(
O	808	809	2
O	809	810	)
O	810	811	/
O	811	814	day
O	814	815	)
O	816	818	or
B-control	819	826	placebo
O	826	827	,
O	828	836	followed
O	837	839	by
O	840	846	repeat
O	847	851	fine
O	851	852	-
O	852	858	needle
O	859	869	aspiration
O	870	873	and
O	874	883	biomarker
O	884	894	assessment
O	894	895	.

O	896	899	The
O	900	904	main
O	905	910	study
O	911	914	end
O	915	920	point
O	921	924	was
O	925	927	an
B-outcome-Measure	928	939	improvement
I-outcome-Measure	940	942	in
I-outcome-Measure	943	952	cytologic
I-outcome-Measure	953	960	pattern
O	960	961	.

O	962	964	Of
B-total-participants	965	968	119
O	969	977	subjects
O	978	985	entered
O	985	986	,
O	987	989	96
O	989	990	%
O	991	1000	completed
O	1001	1004	the
O	1005	1010	study
O	1011	1014	and
O	1015	1019	were
O	1020	1029	evaluable
O	1030	1033	for
O	1034	1037	the
O	1038	1042	main
O	1043	1048	study
O	1049	1052	end
O	1053	1058	point
O	1058	1059	.

O	1060	1061	A
O	1062	1068	modest
O	1069	1078	reduction
O	1079	1080	(
O	1080	1082	28
O	1082	1083	%
O	1083	1084	)
O	1085	1087	in
O	1088	1095	average
B-outcome	1096	1101	total
I-outcome	1102	1107	urine
I-outcome	1108	1118	polyamines
O	1119	1122	was
O	1123	1131	obtained
O	1132	1134	in
O	1135	1138	the
O	1139	1143	DFMO
O	1144	1149	group
O	1149	1150	,
O	1151	1154	but
O	1155	1160	there
O	1161	1164	was
O	1165	1167	no
B-outcome	1168	1177	reduction
I-outcome	1178	1180	in
I-outcome	1181	1184	the
I-outcome	1185	1195	spermidine
I-outcome	1195	1196	:
I-outcome	1196	1204	spermine
I-outcome	1205	1210	ratio
O	1210	1211	.

O	1212	1217	There
O	1218	1221	was
O	1222	1224	no
O	1225	1235	difference
O	1236	1238	in
B-outcome	1239	1248	cytologic
I-outcome	1249	1260	improvement
O	1261	1268	between
O	1269	1273	DFMO
O	1274	1277	and
O	1278	1285	placebo
O	1285	1286	.

O	1287	1295	Likewise
O	1295	1296	,
O	1297	1302	there
O	1303	1306	was
O	1307	1309	no
O	1310	1320	difference
O	1321	1328	between
O	1329	1333	DFMO
O	1334	1337	and
O	1338	1345	placebo
O	1346	1349	for
O	1350	1353	the
O	1354	1363	secondary
O	1364	1367	end
O	1368	1374	points
O	1375	1377	of
B-outcome	1378	1384	breast
I-outcome	1385	1394	molecular
I-outcome	1395	1401	marker
I-outcome	1402	1409	changes
O	1410	1411	(
O	1411	1429	immunocytochemical
O	1430	1440	expression
O	1441	1443	of
O	1444	1457	proliferating
O	1458	1462	cell
O	1463	1470	nuclear
O	1471	1478	antigen
O	1478	1479	,
O	1480	1483	p53
O	1483	1484	,
O	1485	1488	and
O	1489	1498	epidermal
O	1499	1505	growth
O	1506	1512	factor
O	1513	1521	receptor
O	1521	1522	)
O	1522	1523	,
B-outcome	1524	1536	mammographic
I-outcome	1537	1543	breast
I-outcome	1544	1551	density
O	1551	1552	,
B-outcome	1553	1558	serum
I-outcome	1559	1566	insulin
I-outcome	1566	1567	-
I-outcome	1567	1571	like
I-outcome	1572	1578	growth
I-outcome	1579	1585	factor
I-outcome	1586	1587	I
O	1587	1588	:
O	1589	1596	insulin
O	1596	1597	-
O	1597	1601	like
O	1602	1608	growth
O	1609	1615	factor
O	1616	1623	binding
O	1624	1631	protein
O	1632	1633	3
O	1634	1639	ratio
O	1639	1640	,
B-outcome	1641	1648	adverse
I-outcome	1649	1655	events
O	1655	1656	,
B-outcome	1657	1664	quality
I-outcome	1665	1667	of
I-outcome	1668	1672	life
I-outcome	1673	1680	indices
O	1680	1681	,
O	1682	1684	or
B-outcome	1685	1695	subsequent
I-outcome	1696	1702	cancer
I-outcome	1703	1714	development
O	1714	1715	.

O	1716	1720	DFMO
O	1721	1723	at
O	1724	1725	a
O	1726	1730	dose
O	1731	1736	level
O	1737	1739	of
O	1740	1741	0
O	1741	1742	.
O	1742	1743	5
O	1744	1745	g
O	1745	1746	/
O	1746	1747	m
O	1747	1748	(
O	1748	1749	2
O	1749	1750	)
O	1750	1751	/
O	1751	1754	day
O	1755	1767	administered
O	1768	1771	for
O	1772	1773	6
O	1774	1780	months
O	1781	1785	does
O	1786	1789	not
O	1790	1798	modulate
O	1799	1805	breast
O	1806	1810	risk
O	1811	1821	biomarkers
O	1822	1828	tested
O	1829	1831	in
O	1832	1836	this
O	1837	1842	study
O	1842	1843	.
